Hellenic Institute for the Study of Sepsis
At the dawn of the financial crisis in Greece, a group of 14 researchers and clinicians realized the need to struggle to maintain a high level of research and education for sepsis and systemic inflammation that are the main disorders leading to death in our world. This group inaugurated in July 2010 the Hellenic Institute for the Study of Sepsis (HISS), a non-profit, non-commercial organization.
The last eleven years, the Executive Board and the General Assembly are proud to present a very vivid workload summarized as a) continuing support to the investigators of the Hellenic Sepsis Study Group; b) continuing education in sepsis by the organization of thirteen national and international workshops and conferences and by the publications of Greek guidelines in sepsis; c) fifteen completed clinical studies and ten ongoing clinical studies in Greece; four of the clinical trials are international with other European Countries; d) support of PhD theses in sepsis; and e) 72 original publications in international peer-reviewed medical journals.
HISS is pioneer in personalized medicine and is presenting as major achievement the design, conduct, analysis and publication of the double-blind, pivotal trial SAVE-MORE for the successful management of moderate to severe COVID-19 pneumonia with anakinra guided by the biomarker suPAR. This trial was conducted in 37 study sites in Greece and Italy; 606 patients were enrolled and the study received advice from COVID-ETF of the European Medicines Agency. (https://www.nature.com/articles/s41591-021-01499-z.pdf).
The General Assembly
Our success story
Address for correspondence
88 Michalakopoulou Street,
11528 Athens, Greece
Tel/Fax: +30 210 74 80 662
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial
Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: The AIDA open label, randomized, controlled Phase 4 trial
ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial:study protocol
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia